Related Experiment Video

Updated: Nov 19, 2025

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.5K

One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration

Jaya Chandrasekhar1,2, Vera C de Winter2, Deborah N Kalkman2

  • 1The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA.

Cardiovascular Drugs and Therapy
|January 30, 2021
PubMed

Insights

The COMBO stent showed a higher risk of target lesion failure in acute coronary syndromes (ACS) patients compared to non-ACS patients. However, no significant differences in stent thrombosis or target lesion failure were found among ACS subtypes.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Biomaterials

Background:

  • The COMBO stent utilizes biodegradable polymer and endothelial progenitor cell (EPC) capture technology for enhanced endothelialization.
  • This technology may offer benefits in patients with acute coronary syndromes (ACS).

Purpose of the Study:

  • To evaluate the performance of the COMBO stent in patients with ACS compared to non-ACS patients.
  • To analyze COMBO stent outcomes based on ACS subtypes: ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina (UA).

Main Methods:

  • A pooled patient-level dataset (n=3614) from the MASCOT and REMEDEE registries was analyzed.
  • Outcomes were assessed by ACS status and subtype, with a primary endpoint of 1-year target lesion failure (TLF).
  • Secondary outcomes included stent thrombosis (ST).

Main Results:

  • ACS patients (54%) had a higher risk of 1-year TLF compared to non-ACS patients (4.5% vs. 3.3%, HR 1.51, p=0.045).
  • Definite/probable stent thrombosis was not significantly different between ACS and non-ACS groups (1.1% vs. 0.5%, p=0.08).
  • 1-year TLF was similar across ACS subtypes (STEMI, NSTEMI, UA), but definite/probable ST was higher in STEMI patients (1.9%, p=0.03).

Conclusions:

  • The COMBO stent PCI was associated with a slightly increased risk of 1-year TLF in ACS patients versus non-ACS patients.
  • No significant differences in stent thrombosis were observed between these groups.
  • 1-year TLF rates were comparable among STEMI, NSTEMI, and UA patients.
Abstract

Keywords:
Acute coronary syndromeAnti-CD34Dual therapy stentEndothelial progenitor cell capturePercutaneous coronary intervention

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.3K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.0K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
92
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
288
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
96
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
126
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
133
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
149